



**World Health
Organization**

INN Working Document 21.526
01/09/2021

**Addendum¹ to
"The use of stems in the selection of International
Nonproprietary Names (INN) for pharmaceutical
substances" WHO/EMP/RHT/TSN/2018.1**

Programme on International Nonproprietary Names (INN)

***Health Products Policy and Standards (HPS)
Access to Medicines and Health Products (MHP)***

World Health Organization, Geneva

© World Health Organization 2021 - All rights reserved. The contents of this document may not be reviewed, abstracted, quoted, referenced, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means, without explicit prior authorization of the WHO INN Programme.

This document contains the collective views of the INN Expert Group and does not necessarily represent the decisions or the stated policy of the World Health Organization.

Addendum* to "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" - WHO/EMP/RHT/TSN/2018.1

* This addendum is a cumulative list of all new stems selected by the INN Expert Group since the publication of *"The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances"* 2018.

-adenant	adenosine receptors antagonists ciforadenant (118), inupadenant (123), preladenant (99), taminadenant (120), tozadenant (106), vipadenant (103)
-bep	engineered or synthetic scaffolds proteins with non-immunoglobulin variable derived binding domains dazodalibep (123), ensovibep (124), izokibep (122), lerodalcibep (123), taldefgrobep alfa (121), tezatabep matraxetan (122), tifalibep (122)
-bresib	inhibitors of the bromodomain and extra-terminal motif (BET) family of bromodomain (BRD) proteins, antineoplastics alobresib (117), birabresib (115), mivebresib (115), molibresib (116), pelabresib (123), trotabresib (125)
-caftor	cystic fibrosis transmembrane regulator (CFTR) protein modulators, correctors, and amplifiers bamocaftor (121), deutivacaftor (118), dirocaftor (123), elexacaftor (121), galicaftor (119), icenticaftor (122), ivacaftor (104), lumacaftor (105), navocaftor (121), nesolicaftor (122), olacaftor (119), posenacaftor (122), tezacaftor (114)
-calcet/-calcet-	calcium-sensing receptors (CaSR) agonists cinacalcet (88), etelcalcetide (112), evocalcet (113), tecalcet (87), upacalcet (118)
-cerfont	corticotropin-releasing factor (CRF) receptor antagonists crinecerfont (120), emicerfont (102), pexacerfont (97), tildacerfont (119), verucerfont (102)
-copan	complement receptor antagonists/ complement inhibitors avacopan (114), danicopan (119), iptacopan (122), nomacopan (119) to be listed under (c) category: pegcetacoplan (120), zilucoplan (118)

-corat	glucocorticoid receptor agonists
	dagrocorat (111), fosdagrocorat (111), mapracorat (102), tomicorat (108), velsecorat (121)
-dil	vasodilators
-sudil	Rho protein kinase inhibitors
	belumosudil (123), cotosudil (123), fasudil (64), netarsudil (113), ripasudil (109), verosudil (112)
-espib	heat shock protein (HSP) 90 inhibitors (other than –mycin)
	icapamespib (123), ganetespib (105), luminespib (108), onalespib (112), pimitespib (121), zelavespib (123)
-estrant	estrogen antagonists, including estrogen receptor down-regulators
	amcenestrant (122), brilanestrant (115), camizestrant (125), elacestrant (115), fulvestrant (79), giredestrant (122), rintodestrant (123)
-fexor	farnesoid X receptor agonists
	cilofexor (119), nidufexor (118), tropifexor (116), turofexorate isopropyl (103), vonafexor (122)
-fusp	fusion proteins¹
	bintrafusp alfa (121), cinrebafusp alfa (121), clervonafusp alfa (120), dalutrafusp alfa (125), efdamrofusp alfa (125), ensomafusp alfa (125), lepunafusp alfa (125), lorukafusp alfa (120), modakafusp alfa (122), onfekafusp alfa (118), oplunofusp (123), pabinafusp alfa (120), rozibafusp alfa (120), simlukafusp alfa (121), tagraxofusp (118), tebentafusp (118), valanafusp alfa (118)
-golix	gonadotropin releasing hormone (GnRH) antagonists
	elagolix (99), linzagolix (118), opigolix (118), relugolix (107), sufugolix (89)

¹ A fusion protein is defined as a multifunctional protein derived from a single nucleotide sequence which may contain two or more genes or portions of genes with or without amino acid linker sequences. The genes should originally code for separate proteins, with at least two of them endowed with pharmacological action (e.g. action and targeting). “Notes from the fusion protein Working Group”, INN Working Document number 17.414 rev.

-irine	cytotoxic pyrrolobenzodiazepine dimers and analogues
	camidanlumab tesirine (117), loncastuximab tesirine (117), mipasetamab uzoptirine (123), pivekimab sunirine (125), rolinsatamab talirine (119), rovalpituzumab tesirine (114), serclutamab talirine (120), tamrintamab pamozirine (120), vadastuximab talirine (113)
-ixafor	chemokine CXCR4 antagonists
	balixafortide (112), burixafor (104), mavorixafor (118), motixafortide (120), plerixafor (93)
-ixibat	ileal bile acid transporter (IBAT) inhibitors, bile acid reabsorption inhibitors
	barixibat (88), elobixibat (104), linerixibat (118), maralixibat chloride (113), odevixibat (119), volixibat (113)
-leuton	5-lipo-oxygenase inhibitors, anti-inflammatory
	atreleuton (78), diroleuton (118), epeleuton (118), fenleuton (72), setileuton (101), zileuton (63)
-madlin	E3 ubiquitin-protein ligase Mdm2 (Hdm2) inhibitors
	alrizomadlin (125), navtemadlin (124), rebemadlin (125), siremadlin (119), sulanemadlin (123)
	to be listed under category (c): idasanutlin (111), milademetan (117), serdemetan (101)
-meran	messenger RNA (mRNA)
	abdavomeran (124)*, acavameran (124), autogene cevumeran (122), elasomeran (125)*, enomimeran (123), fazulemeran (125), ganulameran (124)*, gindameran (123), nadorameran (113), ontasameran (123), pidacmeran (124)*, pomulmeran (123), tozinameran (124)*, vibosameran (123), zorecimeran (124)*
	<i>*additional prop.INN Lists 124 and 125 – COVID-19 (special edition)</i>
stat	enzyme inhibitors
-becestat	beta secretase inhibitors
	atabecestat (117), elenbecestat (117), umibecestat (119), lanabecestat (116), verubecestat (112)

-glustat	ceramide glucosyltransferase inhibitors duvoglustat (102), eliglustat (103), miglustat (85), sinbaglustat (121), venglustat (114)
-metostat	histone N-methyltransferase inhibitors lirametostat (123), onametostat (123), pemrametostat (123), pinometostat (112), tazemetostat (112), valemestat (118)
-stinel	N-methyl-D-aspartate (NMDA) receptor co-agonists apimostinel (115), gavestinel (77), licostinel (77), rapastinel (111), zelquistinel (121)
-tinib	tyrosine kinase inhibitors
-ertinib	epidermal growth factor receptor (EGFR) inhibitors abivertinib (119), befotertinib (123), canertinib (87), epertinib (115), lazertinib (117), mavelertinib (118), mobocertinib (121), olafertinib (121), osimertinib (113), rezivertinib (122), sunvozertinib (125), tuxobertinib (125), xiliertinib (121), zorifertinib (121) (b) category: ulixertinib (113), ravoxertinib (115) (Erk inhibitors) (c) category: afatinib (104), olmutinib (114), erlotinib (85), gefitinib (85), mubritinib (90), nazartinib (114), mubritinib (90), nazartinib (114)
- trectinib	tropomyosin receptor kinase (TRK) inhibitors entrectinib (113), larotrectinib (115), repotrectinib (120), selitrectinib (120), talrectinib (123)
-tirom(-)	antihyperlipidaemics, thyromimetic derivatives acetiromate (30), axitirome (82), bentiromide (41), eprotirome (99), omzotirome (125), resmetirom (119), sobetirome (100)

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23669

